Premium
Childhood acute lymphoblastic leukemia in the age of genomics
Author(s) -
Carroll William L.,
Bhojwani Deepa,
Min DongJoon,
Moskowitz Naomi,
Raetz Elizabeth A.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20722
Subject(s) - genomics , computational biology , medicine , immunophenotyping , human genome , genome , dna microarray , childhood cancer , microarray , transcriptome , gene , proteome , pediatric cancer , bioinformatics , identification (biology) , blood cancer , cancer , gene expression , biology , genetics , immunology , flow cytometry , botany
The recent sequencing of the human genome and technical breakthroughs now make it possible to simultaneously determine mRNA expression levels of almost all of the identified genes in the human genome. DNA “chip” or microarray technology holds great promise for the development of more refined, biologically‐based classification systems for childhood ALL, as well as the identification of new targets for novel therapy. To date gene expression profiles have been described that correlate with subtypes of ALL defined by morphology, immunophenotype, cytogenetic alterations, and response to therapy. Mechanistic insights into treatment failure have come from the definition of mRNA signatures that predict in vitro chemoresistance, as well as differences between blasts at relapse and new diagnosis. New bioinformatics tools optimize data mining, but validation of findings is essential since “over‐fitting” the data is a common danger. In the future, genomic analysis will be complemented by evaluation of the cancer proteome. © 2005 Wiley‐Liss, Inc.